Association of Vaping and Respiratory Health among Youth in the Population Assessment of Tobacco and Health (PATH) Study Wave 3

• Published in: International journal of environmental research and public health Vol. 18; no. 15; p. 8208
• Main Authors: Cherian, Christie, Buta, Eugenia, Simon, Patricia, Gueorguieva, Ralitza, Krishnan-Sarin, Suchitra
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 03.08.2021; MDPI
• Subjects: Adolescent; Adolescents; Asthma; Cigarettes; Clinical outcomes; Complications; Confidence intervals; Cough; Cross-Sectional Studies; Demographics; Demography; Electronic cigarettes; Electronic Nicotine Delivery Systems; Humans; Inhalers; Nicotiana; Nicotine; Pneumonia; Population; Public health; Regression analysis; Smoking; Statistical analysis; Teenagers; Tobacco; Tobacco Products; United States - epidemiology; Vaping; Vaping - adverse effects; Variables; Wheezing; United States; United States > US; pulmonary; electronic nicotine products (ENP); wheezing; adolescents; cough; public policy
• ISSN: 1660-4601; 1661-7827; 1660-4601
• DOI: 10.3390/ijerph18158208

The purpose of this study is to evaluate the association of electronic nicotine product (ENP) use and its respiratory manifestations in a nationally representative sample of adolescents in the US. Cross-sectional evidence from 9750 adolescents in wave 3 (October 2015-October 2016) of the Population Assessment of Tobacco and Health (PATH) survey was used. Adjusting for demographics, lifetime number of cigarettes and cigars used, home rules about tobacco use, and tobacco used by other household members, we used logistic regression models to examine associations between ENP use and its respiratory manifestations in the past year. Among 9750 adolescents, 12% ( = 1105) used ENP in the past year. Compared to non-users, past-year ENP-users had 37% higher odds of wheezing in general (Adjusted Odds Ratio (AOR) = 1.37, 95% Confidence interval (CI): 1.11-1.71, = 0.005) and higher odds of wheezing 4-12 times or >12 times per year versus no wheezing (AOR = 1.57, 95% CI: 1.01-2.46, = 0.05 and AOR = 2.58, 95% CI: 1.04-6.41, = 0.04, respectively). Additionally, odds of dry cough at night were 23% higher among ENP-users than among non-users (AOR = 1.23, 95% CI: 1.04-1.46, = 0.02). There was no association between past-year ENP use and exercise-induced wheezing or asthma diagnosis. Among those with asthma, there was no evidence of an association between ENP use and long-acting inhaler or quick-relief inhaler use. ENP use among adolescents is associated with increased frequency of wheezing and dry cough. Early recognition of pulmonary clinical manifestations among young ENP users should be critical considerations in regulatory and prevention efforts to protect public health, and clinical efforts to prevent progression to serious pulmonary complications.